This federal contract IDV award is a single-award indefinite delivery contract between the U.S. Department of Veterans Affairs (VA) and the prime contractor RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company. The contract has a total ceiling value of $249,500 and a performance period ending on March 31, 2025. Under this IDV, RLS (USA) Inc. will supply a variety of non-PET radiopharmaceuticals to support nuclear medicine diagnostic services at VA medical centers and military...
This single-award Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) to RLS (USA) Inc., a foreign-owned for-profit radiopharmacy company, to provide radiopharmaceuticals and related supplies to the VA Northern California Health Care System (VANCHCS). The contract has a ceiling value of $2,500,000 and a performance period through March 31, 2030. Under this IDC, RLS (USA) Inc. will deliver radiopharmaceuticals such as gallium-67, fluorodeoxyglucose F-18,...
This federal Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) to RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company. The contract is for the delivery of non-positron emission tomography (non-PET) radiopharmaceuticals to support nuclear medicine diagnostic services at VA medical centers. The contract has a performance period from April 1, 2025, to March 31, 2026, with a ceiling value of $425,725.07. RLS (USA) Inc. is an experienced federal...
This indefinite delivery contract was awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 17 to RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company. The contract has a ceiling value of $4,998,603.38 and a performance period through September 17, 2029. The contract is for the provision of critical radiopharmaceuticals used in nuclear medicine diagnostic services at VA medical centers and military treatment facilities, including gallium-67,...
The Department of Veterans Affairs (VA), Veterans Integrated Service Network 21 has awarded an Indefinite Delivery Contract (IDC) worth up to $1,200,000 to RLS (USA) Inc., a foreign-owned for-profit radiopharmacy company, to provide radiopharmaceuticals and related supplies to VA medical centers and military treatment facilities. The initial task order under this IDC is valued at $179,605.38 and covers the delivery of radiopharmaceuticals such as gallium-67, fluorodeoxyglucose F-18,...
This indefinite delivery contract (IDC) was awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 2 (VISN 2), a civilian agency, to the prime contractor RLS (USA) Inc., a foreign-owned for-profit radiopharmacy company. The contract, valued at $538,493.10, is for the delivery of the radiopharmaceutical product NETSPOT GA-68 to support nuclear medicine imaging procedures at VA medical facilities. RLS (USA) Inc. holds several federal IDV contracts with the VA...
RLS USA Inc. was awarded an indefinite delivery contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 17 to provide radiopharmaceutical products. The potential value of the contract is $1,162,500. No set-aside designation was applied. Under the contract, RLS USA Inc. received two delivery orders to date for radiopharmaceutical supplies. The first delivery order, valued at $244,564.67, was awarded on August 2, 2022 for a performance...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a single award indefinite delivery contract to RLS USA Inc. to provide radiopharmaceutical products and services to the Milwaukee VA Medical Center. The contract has a total value of $648,785.97 to be delivered over a three year period of performance from March 1, 2023 through February 28, 2026. RLS USA Inc. will supply radiopharmaceuticals from its place of performance in Lake...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded an indefinite delivery contract to RLS USA Inc. to provide non-PET radiopharmaceuticals in support of nuclear medicine services. The contract established a potential value of $733,420.11 over its period of performance from October 2021 through September 2024. Delivery orders issued against this contract included awards of $251,729.90, $244,402.04, and $650,585.28 to RLS USA Inc. for...
The Defense Health Agency awarded RLS USA Inc. a single award indefinite delivery contract for radiopharmaceuticals with a potential value of $1,914,116.40 over five years. No set-aside provisions were applied. Under this vehicle, RLS USA Inc. received a firm fixed price delivery order for $299,975.67 to supply unspecified radiopharmaceutical products to the Defense Health Agency from their Tampa, Florida facility between November 2022 through September 2023. Additionally, a $64,238.93 order was...